Purpose Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced
ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting …

Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced
ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity …

Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF)
was shown to be superior to enalapril in reducing the risk of death and hospitalization for …

Background Sacubitril/valsartan reduces mortality in patients with heart failure with reduced
ejection fraction (HFrEF) when compared with enalapril. However, it is unknown the effect of …

Background Impaired exercise capacity is the most disabling symptom in patients with heart
failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced …

Background Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure
with reduced ejection fraction (HFrEF) are often not reached in clinical practice. Objectives …

Background: Sacubitril/valsartan significantly reduced heart failure (HF) hospitalisations and
mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional …

Purpose Sacubitril/valsartan has been demonstrated to improve prognosis and outcomes in
heart failure with reduced ejection fraction (HFrEF) patients. We sought to compare the …

Objective: The cardiopulmonary exercise test (CPET) provides functional prognostic
parameters for patients with chronic heart failure (CHF), such as peak volume of oxygen …

Aims Practice guidelines recommend sacubitril/valsartan for heart failure with reduced
ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real …